2011 is likely to be a defining year for Pfizer Inc. and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as 55-year-old CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. The announcement had the marking of a coup d'état, given the abruptness and the critical juncture of the drugmaker's fortunes. ( See "Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era," "The Pink Sheet" DAILY, December 6, 2010Also see "Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era" - Pink Sheet, 6 December, 2010..)
In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?